Skip to main content
. 2012 Mar 14;6(6):e105–e113. doi: 10.1111/j.1750-2659.2012.00352.x

Table 3.

 Clinical course, treatment, and complications

Overall (n = 100) Wave 1 (n = 19) Wave 2 (n = 81) P
Clinical course and management
 Days of symptoms, median (IQR) 12·5 (6–18) 18 (7–19·25) 10 (6–16·75) 0·149
 Days of fever, median (IQR) 2 (1–4) 2 (1–3) 2 (1–4) 0·443
 Days of viral shedding, median (IQR) 46 (14–85) 98·5 (28·25–157·25) 38 (13–70) 0·034
 Antiviral therapy 89 (89·0) 12 (63·2) 77 (95·1) 0·001
 Early antiviral therapy
  Within 24 hours of symptom onset 36/85 (42·4) 2/11 (18·2) 34/74 (45·9) 0·108
  Within 48 hours of symptom onset 49/85 (57·6) 6/11 (54·5) 43/74 (58·1) 1·000
 Antiviral duration
  Standard (5 days) 70/87 (80·5) 8/11 (72·7) 62/76 (81·6) 0·443
  Extended (>5 days) 17/87 (19·5) 3/11 (27·3) 14/76 (18·4)
 Antibiotic treatment 56 (56·0) 9 (47·4) 47 (58·0) 0·400
 Oxygen supplementation 4 (4·0) 2 (10·5) 2 (2·5) 0·162
 Respiratory complications* 9 (9·0) 1 (5·3) 8 (9·9) 1·000
  Upper respiratory tract 7 (7·0) 1 6
  Asthma exacerbation 2 (2·0) 0 2
 Extra‐respiratory complications 39 (39·0) 8 (42·1) 31 (38·3) 0·758
  Hematologic 50 (50·0) 13 37
  Non‐hematologic 11 (11·0) 5 6
 Laboratory‐confirmed infections 5 (5·0) 1 (5·3) 4 (4·9) 1·000
  Bacterial 2 (2·0) 0 2
  Fungal 1 (1·0) 1 0
  Viral 2 (2·0) 0 2
 Alteration of chemotherapy** 43/82 (52·42) 9/17 (52·9) 34/65 (52·3) 0·963
Severe outcomes
 Hospitalization 51/99 (51·5) 10 (52·6) 41/80 (51·2) 0·914
  Duration, d, median (IQR) 5 (3–13) 8 (4–68·5) 5 (3–10·75) 0·143
 Pneumonia*** 10 (10·0) 2 (10·5) 8 (9·9) 1·000
 ICU admission 1 (1·0) 0 (0·0) 1 (1·2) 1·000
 Need for mechanical ventilation 0 (0·0)
 Death 0 (0·0)

Data are n (%) unless otherwise indicated. Bold values in tables indicate P‐values lower than the significance level α = 0.05.

*Excludes radiologically confirmed pneumonia.

**Denominators exclude patients not scheduled for chemotherapy.

***Radiologically confirmed.

None required ventilation, inotropes, dialysis, or extracorporeal membrane oxygenation.